Navigation Links
Preclinical Research on Coronary Stent with CeloNova BioSciences' Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007

ATLANTA, Sept. 9 /PRNewswire/ -- Celonova Biosciences, Inc. ("CeloNova"), a leading developer of innovative medical devices, today announced that the paper, "Comparison of late in-stent stenosis and vessel wall inflammation in Cypher(R) Select(TM), Taxus(R) Express(TM), and Polyzene(R)-F nanocoated cobalt chromium stents in a porcine coronary artery model" prepared by Dr. Boris Radeleff has been chosen to receive the CIRSE 2007 Magna Cum Laude EPOS Award.

"We are delighted that Dr. Radeleff has been honored by his peers for his work comparing the performance of the leading drug-eluting stents to a stent treated with CeloNova's proprietary Polyzene(R)-F medically inert surface coating," said Thomas A. Gordy, CeloNova President and Chief Executive Officer. "This award validates the high quality of the work undertaken by Dr. Radeleff and his colleagues to understand how Polyzene(R)-F can enhance the performance of coronary stents by inhibiting restenosis and thrombus formation without the need to resort to an anti-proliferative drug or long-term dual antiplatelet medications. We continue to believe, based on this and other ongoing research, that Polyzene(R)-F represents a revolutionary breakthrough in the quest to develop the ideal long-term solution for coronary stenting."

Dr. Radeleff, a physician at the University Hospital of Heidelberg, received his award at the CIRSE Opening Ceremony and Awards Session in Athens, Greece on Saturday, September 08.


The Cardiovascular and Interventional Radiological Society of Europe is a non-profit making, educational and scientific association of 2,300 interventional professionals with an active personal involvement and interest in interventional radiology or cardiovascular imaging techniques.

About CIRSE 2007

The CIRSE Annual Scientific and Postgraduate Educational Meeting has established itself as the premier gathering for all professionals devoted to the field of Cardiovascular and Interventional Radiology in Europe. CIRSE 2007 is a unique forum where medical professionals can meet their colleagues from all around the world, and exchange ideas and information in the field of minimally invasive, image guided therapies.

About CeloNova BioSciences, Inc.

Headquartered near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices based on the company's patented Polyzene(R)-F surface coating technology. Polyzene(R)-F is highly lubricious, and possesses both anti-bacterial and anti-inflammatory properties that make it an ideal surface treatment for implanted medical devices. The company's current product portfolio includes its Embozene(TM) Microspheres, used to treat arteriovenous malformations, hypervascularized tumors, uterine fibroids and hepatocellular carcinoma. Other innovative devices are currently in the company's developmental pipeline. For more information, please visit

Contact: Thomas A. Gordy

President and Chief Executive Officer

+1 770-502-0304

SOURCE CeloNova BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
2. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
3. Control Your siRNA Research
4. Getting Started with MicroRNA Research
5. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
6. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
7. Research Organics
8. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
9. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
10. Research Tools for Analysis of ZAP-70
11. Technical Specifications Accelerating Your Research with the BD FACSCanto High Throughput Sampler Option
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts ... they believe could be a new and helpful biomarker for malignant pleural mesothelioma. ... here to read it now. , Biomarkers are components in the blood, ...
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
Breaking Biology News(10 mins):